References
- Choi, S.Y., et al., 2020. Metformin ameliorates animal models of dermatitis. Inflammopharmacology, 28 (5), 1293–1300.
- Cotto, K.C., et al., 2018. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Research, 46 (D1), D1068–D1073.
- Fan, Y., Habib, M., and Xia, J., 2018. Xeno-miRNet: a comprehensive database and analytics platform to explore xeno-miRNAs and their potential targets. PeerJ., 6, e5650.
- Fan, Y., and Xia, J., 2018. miRNet—functional analysis and visual exploration of miRNA–target interactions in a network context. In: L. von Stechow and A. Santos Delgado, eds. Computational Cell Biology. New York, NY: Springer New York, 215–233.
- Huret, J.-L., et al., 2013. Atlas of genetics and cytogenetics in oncology and haematology in 2013. Nucleic Acids Research, 41 (Database issue), D920–924.
- Khokhar, M., et al., 2020. Perspectives on the role of PTEN in diabetic nephropathy: an update. Critical Reviews in Clinical Laboratory Sciences, 57 (7), 470–483.
- Kluger, M.A., et al., 2013. Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. Kidney International, 83 (5), 865–877.
- Kolling, M., et al., 2017. Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice. Molecular Therapy : The Journal of the American Society of Gene Therapy, 25 (1), 165–180.
- La Sala, L., et al., 2018. Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. Cardiovascular Diabetology, 17 (1), 105.
- Lee, Y.-S., et al., 2010. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone, 47 (5), 926–937.
- Lelongt, B., et al., 2001. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. The Journal of Experimental Medicine, 193 (7), 793–802.
- Lewandowski, K.C., et al., 2011. Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Archives of Medical Science, 2, 294–303.
- Li, S.-Y., et al., 2014. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney International, 86 (2), 358–369.
- Li, W.-D., et al., 2017. Metformin inhibits endothelial progenitor cell migration by decreasing matrix metalloproteinases, MMP-2 and MMP-9, via the AMPK/mTOR/autophagy pathway. International Journal of Molecular Medicine, 39 (5), 1262–1268.
- Luo, M., et al., 2017. MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. Scientific Reports, 7, 43427.
- Lv, Z., and Guo, Y., 2020. Metformin and Its Benefits for Various Diseases. Frontiers in Endocrinology, 11, 191.
- Malekpour-Dehkordi, Z., et al., 2019. Metformin reduces fibrosis factors in insulin resistant and hypertrophied adipocyte via integrin/ERK, collagen VI, apoptosis, and necrosis reduction. Life Sciences, 233, 116682.
- Mastenbroek, T.G., et al., 2015. Platelet-Associated Matrix Metalloproteinases Regulate Thrombus Formation and Exert Local Collagenolytic Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 35 (12), 2554–2561.
- Moczulski, D.K., et al., 2007. Expression pattern of genes in peripheral blood mononuclear cells in diabetic nephropathy. Diabetic Medicine : a Journal of the British Diabetic Association, 24 (3), 266–271.
- Otasek, D., et al., 2019. Cytoscape automation: empowering workflow-based network analysis. Genome Biology, 20 (1), 185.
- Pulito, C., et al., 2017. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discovery, 3, 17022.
- Roy, D., et al., 2020. MicroRNA 21 emerging role in diabetic complications: a critical update. Current Diabetes Reviews, 17 (2), 122–135.
- Santos, M.C.L.G., et al., 2004. Inhibition of human pulpal gelatinases (MMP-2 and MMP-9) by zinc oxide cements. Journal of Oral Rehabilitation, 31 (7), 660–664.
- Sena, C.M., et al., 2010. Diabetes mellitus: new challenges and innovative therapies. The EPMA Journal, 1 (1), 138–163.
- Szklarczyk, D., et al., 2019. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research, 47 (D1), D607–D613.
- Ugarte-Berzal, E., et al., 2019. MMP-9/gelatinase B degrades immune complexes in systemic lupus erythematosus. Frontiers in Immunology, 10, 538.
- Van Lint, P., and Libert, C., 2007. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. Journal of Leukocyte Biology, 82 (6), 1375–1381.
- Vujic, I., et al., 2015. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget, 6 (2), 969–978.
- Wang, J., et al., 2013. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochemistry and Biophysics, 67 (2), 537–546.
- Wornle, M., et al., 2009. Role of matrix metalloproteinases in viral-associated glomerulonephritis. Nephrology, Dialysis, Transplantation : official Publication of the European Dialysis and Transplant Association - European Renal Association, 24 (4), 1113–1121.
- Xu, X., et al., 2014. A glimpse of matrix metalloproteinases in diabetic nephropathy. Current Medicinal Chemistry, 21 (28), 3244–3260.